相似文献
1
[Minimal residual disease before post-remission therapy predicts outcomes in younger adult with intermediate-risk acute myeloid leukemia].
Zhonghua Xue Ye Xue Za Zhi. 2019 Feb 14;40(2):147-151. doi: 10.3760/cma.j.issn.0253-2727.2019.02.011.
2
The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Hematology. 2021 Dec;26(1):179-185. doi: 10.1080/16078454.2021.1880753.
3
Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia.
Haematologica. 2017 Jan;102(1):110-117. doi: 10.3324/haematol.2016.144253. Epub 2016 Aug 18.
4
Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis.
Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):e481-e491. doi: 10.1016/j.clml.2018.07.290. Epub 2018 Jul 17.
5
Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1.
Int J Hematol. 2022 Dec;116(6):892-901. doi: 10.1007/s12185-022-03441-6. Epub 2022 Aug 28.
6
Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete Remission.
Transplant Cell Ther. 2022 Jul;28(7):374.e1-374.e9. doi: 10.1016/j.jtct.2022.04.009. Epub 2022 Apr 13.
7
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
Cancer. 2017 Feb 1;123(3):426-435. doi: 10.1002/cncr.30361. Epub 2016 Sep 22.
8
Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes.
Haematologica. 2017 Sep;102(9):1549-1557. doi: 10.3324/haematol.2017.169136. Epub 2017 Jun 1.
9
A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia.
Haematologica. 2019 Feb;104(2):288-296. doi: 10.3324/haematol.2018.194712. Epub 2018 Aug 9.
10
Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
Ann Hematol. 2018 Oct;97(10):1757-1765. doi: 10.1007/s00277-018-3373-y. Epub 2018 May 22.
本文引用的文献
1
Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
N Engl J Med. 2018 Mar 29;378(13):1189-1199. doi: 10.1056/NEJMoa1716863.
2
[Prognostic Analysis of Minimal Residual Disease from Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplant by Flow Cytometry].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018 Feb;26(1):239-244. doi: 10.7534/j.issn.1009-2137.2018.01.042.
3
History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission.
Am J Hematol. 2017 Oct;92(10):1032-1036. doi: 10.1002/ajh.24834. Epub 2017 Jul 29.
4
Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation.
Biol Blood Marrow Transplant. 2017 Jul;23(7):1064-1071. doi: 10.1016/j.bbmt.2017.03.017. Epub 2017 Mar 15.
5
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.
6
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
Cancer. 2017 Feb 1;123(3):426-435. doi: 10.1002/cncr.30361. Epub 2016 Sep 22.
7
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?
J Clin Oncol. 2016 Feb 1;34(4):329-36. doi: 10.1200/JCO.2015.63.3826. Epub 2015 Dec 14.
8
Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
J Clin Oncol. 2015 Apr 10;33(11):1258-64. doi: 10.1200/JCO.2014.58.3518. Epub 2015 Mar 2.
9
High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML).
Ann Hematol. 2014 Oct;93(10):1685-94. doi: 10.1007/s00277-014-2107-z. Epub 2014 May 21.
10
FISH+CD34+CD38- cells detected in newly diagnosed acute myeloid leukemia patients can predict the clinical outcome.
J Hematol Oncol. 2013 Nov 7;6(1):85. doi: 10.1186/1756-8722-6-85.
Zotero 插件